Breaking News Instant updates and real-time market news.

Mylan upgraded to Outperform at Leerink

As previously reported, Leerink analyst Ami Fadia upgraded Mylan to Outperform from Market Perform, with a $52 price target, citing valuation disconnect given the diversified business and catalyst path.

18

May

13

Nov

MYLMylan

$40.39

-1.13 (-2.72%)

04/12/18

LEER

04/12/18UPGRADELEEROutperform

Mylan upgraded to Outperform from Market Perform at Leerink

04/12/18

MZHO

04/12/18NO CHANGETarget $51MZHOBuy

Mylan should be bought on weakness from Q1 commentary, says Mizuho

Mizuho analyst Irina Koffler says that while Mylan's fundamentals remain unchanged following its investor day, the stock could "see some choppiness" due to Q1 commentary which implies a miss versus consensus expectations. The analyst recommends buying the shares on any weakness and reiterates a Buy rating on the name with a $51 price target.

BTIG analyst Timothy Chung writes that Mylan stock should benefit from the company's Investor Day presentation scheduled for tomorrow while keeping his Buy rating and $55 price target. Chung believes that the stock has been constrained and undervalued due to the pricing erosion in the generics industry this year but expects the company's presentation to focus on its business outside the U.S., where Mylan's revenues account for 60% of the total and are expected to grow in the single digits in 2018. The analyst also anticipates some additional details from Mylan's "complex generic pipeline" at tomorrow's annual investor event.

04/09/18

MSCO

04/09/18NO CHANGEMSCO

Morgan Stanley 'optimistic' two Mylan drugs will get FDA approval by mid-year

Morgan Stanley analyst David Risinger said he sees 4% upside to the firm's FY18 EPS estimate if two Mylan drugs -- generic Advair and biosim Neulasta -- are approved by the FDA, which the firm is "optimistic" will happen by mid-2018. Risinger reiterated an Overweight rating and $50 price target on Mylan shares.